Work Here?
Scorpion Therapeutics
Work Here?
Develops precision oncology drugs through partnerships
Scorpion Therapeutics
Work Here?
Develops precision oncology drugs through partnerships
Overview
Scorpion Therapeutics develops precision oncology drugs that target validated cancer drivers. It designs therapies with high target selectivity and favorable pharmacology, using biology, chemistry, proteomics, and computation, then partners with large pharmaceutical companies to fund and scale development. It differentiates itself through a target-driven science approach and strategic collaborations with milestone and royalty terms. The goal is to deliver fast, precise, and potent cancer treatments and bring them to patients worldwide through partnerships.
About Scorpion Therapeutics
Industries
AI & Machine Learning
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Acquired
Total Funding
$420M
Headquarters
Boston, Massachusetts
Founded
2020
Get referred to Scorpion Therapeutics
See people who can refer or advise you
Simplify's Take
What believers are saying
- Lilly's $2.5 billion deal validated STX-478 and Scorpion's medicinal chemistry.
- Antares launched with $177 million, preserving Scorpion's team and discovery engine.
- Pierre Fabre and AstraZeneca collaborations showed repeatable partnership value beyond one asset.
What critics are saying
- Scorpion ceased as an independent company after Lilly's 2025 acquisition announcement.
- The remaining spinout, Antares, depends on early preclinical programs entering clinic in 2026.
- PI3K inhibitors have a mixed history; STX-478 must outperform entrenched toxicity and efficacy limits.
What makes Scorpion Therapeutics unique
- Scorpion built mutant-selective PI3Kα chemistry, culminating in STX-478 for breast cancer.
- Its platform combines chemical proteomics, machine learning, and precision oncology target selection.
- Lilly kept Scorpion's core asset, validating the team's drug-discovery capabilities.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$420M
Above
Industry Average
Funded Over
4 Rounds
Lightspeed Venture PartnersGrowth & Insights and Company News
6 month growth
↑ 6%1 year growth
↓ -11%2 year growth
↑ 6%The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Antares Therapeutics, Inc. (“Antares”), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, launched...
In conjunction with the funding, Lightspeed Venture partner Shelley Chu will become an investor board member and Frazier Life Sciences managing partner Albert Cha will join the board of Scorpion as an observer.
Scorpion Therapeutics, a Boston, MA-based clinical-stage oncology company, raised $150M in Series C funding
Scorpion Therapeutics appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and expands Leadership Team.
There are no jobs for Scorpion Therapeutics right now.
Find jobs on Simplify and start your career today
About Scorpion Therapeutics
Industries
AI & Machine Learning
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Acquired
Total Funding
$420M
Headquarters
Boston, Massachusetts
Founded
2020
There are no jobs for Scorpion Therapeutics right now.
Find jobs on Simplify and start your career today